By Rick Winterson Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge. It has now established its global headquarters on Fan Pier in South ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...
Hosted on MSN15d
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decadesCNBC's Becky Quick reports on the latest news. Income Tax Reduced For Millions of Americans UMass Found Not Guilty After Student’s $10K Prize Money Gets Rescinded Over Halftime Contest How One ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted. No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback